Inhibition of In Vitro Clot Growth by r-Hirudin Is More Effective and Longer Sustained than by an Analogous Peptide

Summary

The specific thrombin inhibitors r-hirudin and a synthetic peptide (I) _D -FPRP(G)₄-NGDFEEIPEEYL were compared in in vitro tests, r-hirudin proved to be the superior compound with respect to inhibition of amidolytic small substrate turnover that is catalysed by soluble and immobilised thrombin as well as to inhibition of fibrinogen activation. In an in vitro clot model significantly higher molar concentrations of peptide I are needed to achieve fibrin bound thrombin inhibition equivalent to that of r-hirudin. Stable complexes consisting of thrombin and hirudin oppose labile complexes containing the synthetic peptide. The latter leads to a regaining of thrombin activity with subsequent additional fibrin accretion. Analyses of the mixtures of thrombin and peptide I display a time dependent release of amino-terminal _D -FPR peptide (III) exhibiting, similar to the residual fragment (peptide II), only weak inhibitory activity. Peptide I and the carboxy-terminal fragment induce, within a certain concentration range, an increase in thrombin activity and clot growth.

• References

• 1 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci 1989; 86: 3619-23
• 2 Markwardt F. Hirudin: the promising antithrombotic. Cardiovasc Drug Rev 1992; 10: 211-32
• 3 Agnelli G, Pascucci C, Cosmi B, Nenci GG. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Thromb Haemostas 1990; 63: 204-7
• 4 Kaiser B, Simon A, Markwardt F. Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis. Thromb Haemostas 1990; 63: 44-7
• 5 Doutremepuich C, Lalanne MC, Doutremepuich F, Walenga I, Fareed J, Breddin HK. Comparative study of three recombinant hirudins with heparin in an experimental venous thrombosis model. Haemostas 1991; 21: 99-106
• 6 Sarembrock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991; 84: 232-43
• 7 Grütter MG, Priestle JP, Rahuel J, Grossenbacher H, Bode W, Hofsteenge J, Stone SR. Crystal structure of the thrombin-hirudin-complex: a novel mode of serine protease inhibition. EMBO J 1990; 9: 2361-5
• 8 Di MaioJ, Gibbs B, Munn D, Lefebvre J, Ni F, Konishi Y. Bifunctional thrombin inhibitors based on the sequence of hirudin. J Biol Chem 1990; 265: 21698-703
• 9 Chang JY. Production, properties and thrombin inhibitory mechanism of hirudin amino-terminal core fragments. J Biol Chem 1990; 265: 22159-66
• 10 Naski MC, Fenton JW, Maraganore JM, Oslon ST, Shafer JA. The COOH- terminal domain of hirudin. J Biol Chem 1990; 265: 13484-9
• 11 Schmitz T, Rothe M, Dodt J. Mechanism of the inhibition of alpha-thrombin by hirudin-derived fragments hirudin (1-47) and hirudin (45-65). Eur J Biochem 1991; 195: 251-6
• 12 Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. Design and characterization of Hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochem 1990; 29: 7095-101
• 13 Witting JT, Bourdon P, Maraganore JM. Fenton JW. Hirulog-1 and -B₂ thrombin specificity. Biochem J 1992; 287: 663-4
• 14 Klement P, Borm A, Hirsh J, Maraganore JM, Wilson G, Weitz J. The effect of thrombin inhibitors on tissue plasminogen activation induced thrombolysis in a rat model. Thrornb Haemostas 1992; 68: 64-8
• 15 Rubens FD, Weitz JI, Brash JL, Kinlough-Rathbone RL. The effect of antithrombin Ill-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene. Thromb Haemostas 1993; 69: 130-4
• 16 von ClaussA. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46
• 17 Witting JI, Bourdon P, Brezniak DV, Maraganore JM, Fenton J WII. Thrombin-specific inhibition by and slow cleavage of Hirulog-1. Biochem J 1992; 283: 737-43
• 18 Dennis S, Wallace A, Hofsteenge J, Stone RS. Use of fragments of hirudin to investigate thrombin-hirudin interaction. Eur J Biochem 1990; 188: 61-6
• 19 Liu LW, Ye J, Johnson AE, Esmon CT. Proteolytic formation of either of the two prothrombin activation intermediates results in formation of a hirugen-binding site. J Biol Chem 1991; 266: 23632-6
• 20 Agnelli G, Pascucci C, Cosmi B, Nenci GG. Effects of hirudin and heparin on the binding of new fibrin to the thrombus in t-PA treated rabbits. Thromb Haemostas 1991; 66: 592-7
• 21 Maraganore JM, Oshima T, Asai F, Sugitachi A. Comparison of anticoagulant and antithrombotic activities of Hirulog-1 and argatroban (MD-805). Thromb Haemostas 1991; 65: 651-17
• 22 Kline T, Hammond C, Bourdon P, Maraganore JM. Hirulog peptides with scissile bond replacement resistant to thrombin cleavage. Biochem Biophys Res Commun 1991; 177: 1049-55